About us
- >
- About us >
- Information >
- Announcement
2024-12-05
Energenesis Biomedical has received CRO notification that its Phase I IND application for "ENERGI-F705PD," an oral Parkinson's treatment, has been conditionally approved by the Ministry of Health and Welfare to begin clinical trials.
The Phase I IND application for the oral medication "ENERGI-F705PD," developed by the Company for Parkinson’s Disease, has been conditionally approved by the Ministry of Health and Welfare, enabling the trial to commence recruitment.